某妇幼保健院终止妊娠药品合理使用分析

doi:10.19803/j.1672-8629.2020.11.14

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (11): 813-817.
DOI: 10.19803/j.1672-8629.2020.11.14

某妇幼保健院终止妊娠药品合理使用分析

王海晴, 王晓莉, 陈小红, 陈琳^*

重庆市妇幼保健院,重庆 401120

收稿日期:2020-11-10 修回日期:2020-11-10 出版日期:2020-11-15 发布日期:2020-11-10
通讯作者: ^*陈琳,女,在读博士,副主任药师,临床药学。E-mail：clfxmm@163.com
作者简介:王海晴,女,硕士,药师,药剂学。
基金资助:
重庆市技术创新与应用示范（社会民生类）一般项目（cstc2018jscx-msybX0101）：基于药师专科门诊模式的妊娠期用药安全研究及推广应用

Rational Use of Pregnancy Termination Drugs in a Maternal and Child Health Care Hospital

WANG Haiqing, WANG Xiaoli, CHEN Xiaohong, CHEN Lin^*

Chongqing Health Center for Women and Children, Chongqing 401120, China

Received:2020-11-10 Revised:2020-11-10 Online:2020-11-15 Published:2020-11-10

摘要/Abstract

摘要： 目的分析终止妊娠药品的使用情况,探讨其合理性,为临床合理用药提供参考。方法利用合理用药监测系统和医院信息系统,抽取重庆市妇幼保健院2017~2018年每季度门/急诊使用终止妊娠药品病例100份,住院病例50份,共计1 200份,数据汇总后对终止妊娠药品的临床诊断、用法用量、合并用药及不合理用药情况进行分析。结果随机抽取的1 200例使用终止妊娠药品患者的平均年龄为（29.0±5.2）岁,涉及临床诊断除早期人工流产、妊娠中/晚期引产外,其他诊断占29.25%。常见的与终止妊娠药品合并用药,包括中成药、抗菌药物、雌孕激素类药物（避孕药）、术中用药以及预防/治疗产后出血药。最主要的不合理用药为药品用法用量不适宜,占所有不合理用药的48.5%。结论终止妊娠药品合理使用率逐渐提高,但其中仍存在不合理使用情况,应当持续改进。

关键词: 人工流产, 终止妊娠药品, 用药分析, 合理用药

Abstract: Objective To analyze the usage of pregnancy termination drugs in a Maternal and Child Health Hospital, and probe its rationality so as to provide data for clinical rational drug application. Methods The prescription automatic screening system (PASS) and HIS system were used to retrieve data from medical records, involving 100 records of outpatients and emergency patients and 50 hospitalizations in 2017 and 2018. The clinical diagnosis, usage and dosage, combined use and improper use of drugs for termination of pregnancy were analyzed after the data of eight quarters was summarized. Results The average age of 1,200 randomly selected patients who used drugs for terminating pregnancy was (29.0±5.24)y. In addition to early induced abortion and middle//late pregnancy induced labor, other diagnoses involving drug pregnancy termination accounted for 29.25%, such as missed abortion, postoperative and ectopic pregnancy. Common drugs used in combination with pregnancy termination drugs included Chinese patent medicines, antimicrobial agents, estrogen and progesterone drugs (contraceptives), intraoperative medications and drugs for the prevention/treatment of postpartum bleeding. The irrational usage of drugs for termination of pregnancy mainly involved inappropriate drug usage and dosage, accounting for 48.5%. Conclusion From 2017 to 2018, the percentage of rational use of pregnancy termination drugs in our hospital gradually increased from 80.67% to 97.33%, but there are still cases of irrational use, which should be improved continuously.

Key words: induced abortion, pregnancy termination drugs, analysis of clinical medication, rational drug use

中图分类号:

R969.3

王海晴, 王晓莉, 陈小红, 陈琳. 某妇幼保健院终止妊娠药品合理使用分析[J]. 中国药物警戒, 2020, 17(11): 813-817.

WANG Haiqing, WANG Xiaoli, CHEN Xiaohong, CHEN Lin. Rational Use of Pregnancy Termination Drugs in a Maternal and Child Health Care Hospital[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 813-817.

参考文献

[1] Cheng L N.The current situation and thinking of artificial abortion in China[J]. Chinese Journal of Practical Gynecology and Obstetrics(中国实用妇科与产科杂志), 2012, 28(9): 641-642.
[2] Cheng Y M, Ren S S.The current situation, problems and counter-measures of artificial abortion service in China[J]. Chinese Journal of Family Planning & Gynecotokology(中国计划生育和妇产科), 2011, 3(5): 5-8.
[3] WHO. Clinical Practice Handbook for Safe Abortion[S/OL].(2014-01-20)(2019-11-16)https://www.who.int/reproductivehealth/publications/unsafe_abortion/clinical-practice-safe-abortion/en/.
[4] Chinese Medical Association Family Planning Branch. Guidelines for the application of mifepristone and misoprostol to terminate 8-16 weeks of pregnancy[J]. Chinese Journal of Obstetrics and Gynecology(中华妇产科杂志), 2015(5): 321-322.
[5] Wang X H.Comparison of the efficacy of medical abortion and painless artificial abortion in terminating early pregnancy[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志), 2015, 8(12): 107-108.
[6] Wang C H.Application of mifepristone in induction of labor[J]. Chinese Journal of Practical Gynecology and Obstetrics(中国实用妇科与产科杂志), 2002, 18(5): 13-14.
[7] Shah Deepa,Rijal Pappu,Thakur Achala,et al.Mifepristone and Misoprostol vs Misoprostol Alone in Second Trimester Termination of Pregnancy[J]. Journal of the Nepal Medical Association,2018, 56(213):856-860.
[8] Tan Yiling,Singh Kuldip,Tan Kok Hian,et al.Acceptability and feasibility of outpatient medical abortion with mifepristone and misoprostol up to 70 days gestation in Singapore[J]. European Jjournal of Oobstetrics Ggynecology, and Rreproductive Bbiology, 2018(229):144-147.
[9] Li LM, Gao WL, Chen SP, et al.Effect of mifepristone and misoprostol on induction of labor in late pregnancy[J]. Chinese Journal of Obstetrics and Gynecology(中华妇产科杂志), 1996, 31(11): 684.
[10] Deng Q, Liu L, Ding S W, et al.Clinical study of two application regimens of methotrexate combined with mifepristone in the treatment of ectopic pregnancy[J]. Journal of Practical Obstetrics and Gynecology(实用妇产科杂志), 2010, 26(10): 764-766.
[11] Zhang YJ, Yang YH, Lu F.Expert consensus on treatment of incomplete abortion with traditional Chinese medicine[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2019, 34(8): 3625-3629.
[12] Wei R.Analysis of irrational outpatient prescriptions and measure for improvement[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2012, 9(6): 374-376.
[13] Yu XL, Gu XY, Liu XY, et al.Chinese expert consensus on the application of prophylactic antibiotics for artificial abortion[J]. Chinese Journal of Family Planning & Gynecotokology(中国计划生育和妇产科), 2019, 11(8): 10-12.
[14] National Health and Family Planning Commission of the People's Republic of China. Provisions for the prohibition of fetal gender identification and selection of gender for artificial termination of pregnancy for non-medical needs. [EB/OL].(2016-04-12)(2019-11-16)http://www.nhc.gov.cn/fzs/s3576/201604/53498882be944b f4a51926f059403ac0.shtml.
[15] Jiang YF, Han L, Shi XK.Analysis on drug application of pregnancy termination in early trimester on 9591 prescriptions in Xuzhou Mmaternal and Cchild Hhealth Ccare Hhospital[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2018, 18(2): 237-239.
[16] Zhang S, Lin Q, Deng W, et al.Analysis of 1189 cases of adverse drug relations induced by carboprost methylate[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(6): 374-378, 380.
[17] Cui YT.The clinical effect and safety of oral drospirenone and ethinyl estradiol tablets for contraception after artificial abortion[J]. Medical Equipment(医疗装备), 2019, 32(16): 113-114.

某妇幼保健院终止妊娠药品合理使用分析

Rational Use of Pregnancy Termination Drugs in a Maternal and Child Health Care Hospital

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	黎杏仁, 沈爱宗, 苏丹. 质子泵抑制剂预防胆胰外科围术期应激性黏膜病变的合理性评价[J]. 中国药物警戒, 2023, 20(9): 1022-1026.
[4]	史香芬, 孙志勇, 张旭锋, 卢晓静, 杜书章, 张晓坚. 基于智能信息管理系统的门诊麻精药品全流程管理[J]. 中国药物警戒, 2023, 20(8): 899-903.
[5]	霍艳飞, 田月洁, 许莉莉, 谢彦军, 常虹, 孙春晓, 李霞. 535例氢溴酸高乌甲素制剂新的和严重的药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(8): 921-926.
[6]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[7]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[8]	范秀丛, 董晓慧, 陈丹霞, 鲍思蔚, 马雅斌. 1例妊娠期艰难梭菌感染伴尿路感染患者的药学监护[J]. 中国药物警戒, 2023, 20(5): 579-582.
[9]	殷进军, 王淑伟, 邵姜超, 王冰. 基于加权TOPSIS法的贝伐珠单抗注射液药物利用评价[J]. 中国药物警戒, 2023, 20(12): 1421-1426.
[10]	刘斌, 邵美玲, 蔡怡然, 马丰懿, 兰鸿. 戴明环循环管理在提高门诊处方合理率中的应用价值[J]. 中国药物警戒, 2022, 19(9): 1035-1039.
[11]	庄红艳, 臧彦楠, 刘珊珊, 牛梦溪, 房萌, 尹冬青, 果伟. 唑吡坦致神经精神系统不良反应分析[J]. 中国药物警戒, 2022, 19(8): 889-892.
[12]	马冰冰, 张晓朦, 张冰, 林志健, 吕锦涛. 基于文献分析的老年人中成药合理用药与药学服务思考[J]. 中国药物警戒, 2022, 19(6): 595-599.
[13]	李晓菲, 程蓉, 吴雪梅, 刘智. 注射用特利加压素的安全性分析[J]. 中国药物警戒, 2022, 19(6): 654-656.
[14]	陈方方, 张红旭. 大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的药学实践[J]. 中国药物警戒, 2022, 19(4): 446-449.
[15]	靳浩槟, 郑磊, 杨静, 管玉瑶, 张晓丽. 住院患者皮肤药品不良反应及伴随的肝肾功能异常分析[J]. 中国药物警戒, 2022, 19(3): 310-312.